News Home

Should You Buy Synthetic Biologics Inc (SYN) Stock on Friday?

Friday, June 11, 2021 10:05 AM | InvestorsObserver Analysts
Should You Buy Synthetic Biologics Inc (SYN) Stock on Friday?

Overall market sentiment has been high on Synthetic Biologics Inc (SYN) stock lately. SYN receives a Bullish rating from InvestorsObserver's Stock Sentiment Indicator.

Sentiment Score - ,bullish
Synthetic Biologics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on SYN!

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.

Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.

InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.

For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With SYN Stock Today?

Synthetic Biologics Inc (SYN) stock has fallen -4.79% while the S&P 500 has risen 0.13% as of 10:03 AM on Friday, Jun 11. SYN is down -$0.03 from the previous closing price of $0.72 on volume of 1,181,459 shares. Over the past year the S&P 500 has risen 33.06% while SYN has risen 53.33%. SYN lost -$0.59 per share in the over the last 12 months.

To screen for more stocks like Synthetic Biologics Inc click here.

More About Synthetic Biologics Inc

Synthetic Biologics is a late-stage biotechnology company focused on developing gut microbiome therapeutics. Its portfolio includes SYN-010, which is intended to treat the underlying causes of irritable bowel syndrome with constipation; and SYN-004 (ribaxamase), which aims to defend the gut microbiome from the effects of regularly used intravenous drugs for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antibiotic-resistant organisms. The company is also developing monoclonal antibody therapies for the treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria.

Click Here to get the full Stock Score Report on Synthetic Biologics Inc (SYN) Stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App